Could a cheap drug transform sickle cell care for african kids?
NCT ID NCT06171217
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests the drug hydroxyurea in 811 children with sickle cell anemia across Africa. The goal is to see if it is safe and effective, and to make it more available. Children take daily doses adjusted for their weight, and doctors monitor blood counts and fetal hemoglobin levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxyurea
What this could lead to
If successful, this could make hydroxyurea widely available for children with sickle cell anemia in Africa, reducing pain crises and complications.
What could go wrong
This is a phase II trial, so results are still early. Hydroxyurea can cause bone marrow suppression and may not work for all children. Long-term benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Monkole
Kinshasa, Democratic Republic of the Congo
-
Hospital Pediátrico David Bernardino
Luanda, Angola
-
KEMRI/Wellcome Trust Research
Kilifi, Kenya
-
Mbale Regional Hospital
Mbale, Uganda